Patents by Inventor Yasmina Noubia Abdiche

Yasmina Noubia Abdiche has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-SPIKE GLYCOPROTEIN ANTIBODIES AND THE THERAPEUTIC USE THEREOF
    Publication number: 20230250158
    Abstract: The present application relates to neutralizing antibodies or antigen-binding fragments thereof against betacoronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to nucleic acid(s) encoding such neutralizing antibodies or antigen-binding fragments thereof, and to mixture and compositions comprising such antibodies, antigen-binding fragments or nucleic acids. Such neutralizing antibodies or antigen-binding fragments thereof are able to block betacoronavirus entry into cells and/or to induce complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cellular phagocytosis (ADCP) against betacoronavirus-infected cells. Methods and uses of the antibodies, antigen-binding fragments thereof, nucleic acid(s) or compositions, including therapeutic, diagnostic, and preventative methods and uses for betacoronavirus infections and related diseases such as COVID-19, are also described.
    Type: Application
    Filed: February 23, 2023
    Publication date: August 10, 2023
    Inventors: Ilse Roodink, Yasmina Noubia Abdiche, Jennifer L. Bath
  • Anti-spike glycoprotein antibodies and the therapeutic use thereof
    Patent number: 11623949
    Abstract: The present application relates to neutralizing antibodies or antigen-binding fragments thereof against betacoronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to nucleic acid(s) encoding such neutralizing antibodies or antigen-binding fragments thereof, and to mixture and compositions comprising such antibodies, antigen-binding fragments or nucleic acids. Such neutralizing antibodies or antigen-binding fragments thereof are able to block betacoronavirus entry into cells and/or to induce complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cellular phagocytosis (ADCP) against betacoronavirus-infected cells. Methods and uses of the antibodies, antigen-binding fragments thereof, nucleic acid(s) or compositions, including therapeutic, diagnostic, and preventative methods and uses for betacoronavirus infections and related diseases such as COVID-19, are also described.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: April 11, 2023
    Assignee: Talem Therapeutics LLC
    Inventors: Ilse Roodink, Yasmina Noubia Abdiche, Jennifer L. Bath
  • ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220249657
    Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.
    Type: Application
    Filed: April 20, 2022
    Publication date: August 11, 2022
    Applicant: RINAT NEUROSCIENCE CORP.
    Inventors: Yasmina Noubia Abdiche, Helen Kim Cho, Wei-Hsien Ho, Karin Ute Jooss, Arvind Rajpal, Sawsan Youssef
  • ANTI-SPIKE GLYCOPROTEIN ANTIBODIES AND THE THERAPEUTIC USE THEREOF
    Publication number: 20220251174
    Abstract: The present application relates to neutralizing antibodies or antigen-binding fragments thereof against betacoronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to nucleic acid(s) encoding such neutralizing antibodies or antigen-binding fragments thereof, and to mixture and compositions comprising such antibodies, antigen-binding fragments or nucleic acids. Such neutralizing antibodies or antigen-binding fragments thereof are able to block betacoronavirus entry into cells and/or to induce complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cellular phagocytosis (ADCP) against betacoronavirus-infected cells. Methods and uses of the antibodies, antigen-binding fragments thereof, nucleic acid(s) or compositions, including therapeutic, diagnostic, and preventative methods and uses for betacoronavirus infections and related diseases such as COVID-19, are also described.
    Type: Application
    Filed: January 27, 2022
    Publication date: August 11, 2022
    Inventors: Ilse ROODINK, Yasmina Noubia ABDICHE, Jennifer L. BATH
  • Anti-PD-1 antibodies and methods of use thereof
    Patent number: 11338035
    Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: May 24, 2022
    Assignee: RINAT NEUROSCIENCE CORP.
    Inventors: Yasmina Noubia Abdiche, Helen Kim Cho, Wei-Hsien Ho, Karin Ute Jooss, Arvind Rajpal, Sawsan Youssef
  • Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same
    Publication number: 20220056114
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: March 16, 2021
    Publication date: February 24, 2022
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200368349
    Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.
    Type: Application
    Filed: April 13, 2020
    Publication date: November 26, 2020
    Applicant: RINAT NEUROSCIENCE CORP.
    Inventors: Yasmina Noubia Abdiche, Helen Kim Cho, Wei-Hsien Ho, Karin Ute Jooss, Arvind Rajpal, Sawsan Youssef
  • Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same
    Publication number: 20200247878
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: September 17, 2019
    Publication date: August 6, 2020
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • Anti-PD-1 antibodies and methods of use thereof
    Patent number: 10660953
    Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: May 26, 2020
    Assignee: RINAT NEUROSCIENCE CORP.
    Inventors: Yasmina Noubia Abdiche, Helen Kim Cho, Weihsien Ho, Karin Ute Jooss, Arvind Rajpal, Sawsan Youssef
  • Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide
    Patent number: 10329343
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: June 25, 2019
    Assignee: Teva Pharmaceuticals International GmbH
    Inventors: Joerg Zeller, Kristian Todd Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same
    Publication number: 20190092841
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: April 18, 2018
    Publication date: March 28, 2019
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190083612
    Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.
    Type: Application
    Filed: November 12, 2018
    Publication date: March 21, 2019
    Applicant: RINAT NEUROSCIENCE CORP.
    Inventors: YASMINA NOUBIA ABDICHE, HELEN KIM CHO, WEIHSIEN HO, KAREN UTE JOOSS, ARVAND RAJPAL, SAWSAN YOUSSEF
  • Anti-PD-1 antibodies and methods of use thereof
    Patent number: 10155037
    Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: December 18, 2018
    Assignee: Rinat Neuroscience Corp.
    Inventors: Yasmina Noubia Abdiche, Weihsien Ho, Arvind Rajpal, Sawsan Youssef
  • METHODS FOR TREATING HEADACHE USING ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE
    Publication number: 20180162931
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: January 30, 2018
    Publication date: June 14, 2018
    Inventors: Joerg Zeller, Kristian Todd Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • Antagonist antibodies directed against calcitonin gene-related peptide
    Patent number: 9890211
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: February 13, 2018
    Assignee: Teva Pharmaceuticals International GmbH
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • Antagonist antibodies directed against calcitonin gene-related peptide
    Patent number: 9890210
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: February 13, 2018
    Assignee: Teva Pharmaceuticals International GmbH
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide
    Patent number: 9884908
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: February 6, 2018
    Assignee: Teva Pharmaceuticals International GmbH
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide
    Patent number: 9884907
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: February 6, 2018
    Assignee: Teva Pharmaceuticals International GmbH
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • Antagonist Antibodies Directed Against Calcitonin Gene- Related Peptide
    Publication number: 20170240622
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 24, 2017
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • Antagonist Antibodies Directed Against Calcitonin Gene- Related Peptide
    Publication number: 20170240624
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 24, 2017
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal